Wesley Scott St Clair, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 579 Greenway Rd, Suite 200, Boone, NC 28607 Phone: 828-262-0100 Fax: 828-264-7592 |
Patricia Ann Geiger, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 614 Howard Street, Asu, Boone, NC 28608 Phone: 828-262-3100 Fax: 828-262-6262 |
Dr. Dykes Taylor Rushing, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: Student Health, Appalachian State University, 614 Howard Street, Box 32070, Boone, NC 28608 Phone: 828-262-3100 Fax: 828-262-6262 |
Gregory Lynn Adams, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 579 Greenway Rd, Suite 200, Boone, NC 28607 Phone: 828-262-0100 Fax: 828-264-7592 |
Ila Evans Baugham, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2359 Highway 105, Boone, NC 28607 Phone: 828-265-5391 Fax: 828-265-5394 |
Clinton Ballard Zimmerman Jr., MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 579 Greenway Rd, Suite 200, Boone, NC 28607 Phone: 828-262-0100 Fax: 828-264-7592 |
John Robert Lonas, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 579 Greenway Rd, Suite 200, Boone, NC 28607 Phone: 828-262-0100 Fax: 828-264-7592 |
News Archive
Temporarily disabling a single protein inside our cells might be able to protect us from the common cold and other viral diseases, according to a study led by researchers at Stanford University and University of California-San Francisco.
On May 21, 2010, Kathleen Sebelius, Secretary of Health and Human Services announced the addition of Severe Combined Immunodeficiency - commonly known as bubble boy disease - to the core panel of 29 genetic disorders - as part of her recommendation to adopt the national Recommended Uniform Screening Panel.
The moment a bacterial pathogen makes contact with its host, its goal is simple: to infect.
A study in the April 1 issue of the journal SLEEP demonstrates that low socioeconomic status independently predicts the poor acceptance of continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea, and patients with higher incomes are more likely to begin treatment.
Pevion Biotech, the Swiss vaccine company, today announced that it has successfully completed the preclinical safety and efficacy studies of its RSV vaccine candidate PEV4. The vaccine candidate is a modern subunit vaccine candidate against respiratory syncytial virus (RSV), which is based on a recombinant RSV-F protein formulated with Pevion Biotech's proprietary and market-validated virosome technology platform.
› Verified 3 days ago